Improving Clinical Trial Outcomes for New Endometriosis Drugs Using Immune System Derived Epigenetic Biomarkers (EpiMarkers)

Improving Clinical Trial Outcomes for New Endometriosis Drugs Using Immune System Derived Epigenetic Biomarkers (EpiMarkers)

New Research into the Untapped Potential of Immune System Epigenetic Biomarkers and Liquid Biopsies for Assessing Disease Background and Drug Response Heterogeneity
A White Paper by Adam Marsh, Ph.D. Chief Science Officer and Co-Founder

Download the PDF